	US 12,440,485 B2
	Centrally-active ghrelin agonist and medical uses thereof
Claudio Giuliano, Como (IT); Claudio Pietra, San Martino Siccomario (IT); Silvina Garcia Rubio, Princeton, NJ (US); Angelo Guainazzi, New York, NY (US); and Marielle Martinez-Loi, Biasca (CH)
Assigned to Helsinn Healthcare SA, Pazzallo-Lugano (CH)
Filed by Helsinn Healthcare SA, Pazzallo-Lugano (CH)
Filed on May 2, 2024, as Appl. No. 18/653,685.
Application 18/653,685 is a continuation of application No. 16/982,107, granted, now 12,005,056, previously published as PCT/EP2019/056438, filed on Mar. 14, 2019.
Claims priority of application No. 18163425 (EP), filed on Mar. 22, 2018.
Prior Publication US 2024/0293388 A1, Sep. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4468 (2006.01)

CPC A61K 31/4468 (2013.01)

28 Claims

1. A compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt in a crystalline form, wherein said compound has an Xray Powder Diffraction (XRPD) pattern comprising peaks at about 4.1° 2θ, about 8.2° 2θ, about 12.3° 2θ, about 23.7° 2θ, and about 25.2° 2θ.